Provided by Tiger Fintech (Singapore) Pte. Ltd.

BiomX Inc.

0.4691
-0.0209-4.27%
Post-market: 0.49870.0296+6.31%19:52 EDT
Volume:681.39K
Turnover:325.40K
Market Cap:12.28M
PE:-0.22
High:0.5375
Open:0.5000
Low:0.4440
Close:0.4900
Loading ...

BiomX Inc. Earnings Call: Optimism and Progress

TIPRANKS
·
17 May

BiomX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
16 May

Biomx Inc. : H.c. Wainwright Cuts Target Price to $15 From $21

THOMSON REUTERS
·
16 May

BiomX Inc. Reports Q1 2025 Progress and Financials

TIPRANKS
·
16 May

Biomx Reports First Quarter 2025 Financial Results

Reuters
·
15 May

BiomX Q1 EPS $(0.33) Beats $(0.42) Estimate

Benzinga
·
15 May

Biomx Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

THOMSON REUTERS
·
15 May

Biomx Inc - Net Loss $7.7 Mln in Q1 2025

THOMSON REUTERS
·
15 May

Press Release: BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

Dow Jones
·
15 May

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
18 Apr

BiomX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

BiomX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 Apr

Biomx Announces Compliance With Nyse Guidelines on Audit Opinion Disclosure

THOMSON REUTERS
·
01 Apr

Biomx Inc. : H.c. Wainwright Raises Target Price to $21 From $2

THOMSON REUTERS
·
01 Apr

BRIEF-BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

Reuters
·
31 Mar

Biomx Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 for the Treatment of Diabetic Foot Osteomyelitis (Dfo)

THOMSON REUTERS
·
31 Mar

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

GlobeNewswire
·
31 Mar

BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026

Benzinga
·
25 Mar

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire
·
25 Mar

Biomx to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

THOMSON REUTERS
·
20 Mar